E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
vaccination against HPV infection/related disease |
|
E.1.1.1 | Medical condition in easily understood language |
vaccination against HPV infection/related disease |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10071147 |
E.1.2 | Term | Human papilloma virus immunization |
E.1.2 | System Organ Class | 100000004865 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1)To demonstrate that a 3-dose regimen of V501 will reduce the combined incidence of HPV 6-, 11-, 16- or 18-related persistent infection detected in samples from two or more consecutive visits (±1 month visit windows) 6 month or longer apart compared with placebo in 16- to 26-year-old Japanese men who are seronegative at Day 1 and polymerase chain reaction (PCR) negative Day 1 through Month 7 to the relevant HPV type.
2)To demonstrate that a 3-dose regimen of V501 to 16- to 26-year-old Japanese men is generally well tolerated.
|
|
E.2.2 | Secondary objectives of the trial |
1)To demonstrate that a 3-dose regimen of V501 will reduce the combined incidence of HPV 6-, 11-, 16- or 18-related persistent infection, condyloma acuminata, penile/perianal/perineal intraepithelial neoplasia (PIN), penile, perianal or perineal cancer compared with placebo in 16- to 26-year-old Japanese men who are seronegative at Day 1 and PCR negative Day 1 through Month 7 to the relevant HPV type. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Merck will conduct Future Biomedical Research on DNA (blood) specimens collected during this clinical trial. Such research is for biomarker testing to address emergent questions not described elsewhere in the protocol (as part of the main trial) and will only be conducted on specimens from appropriately consented subjects. The objective of collecting specimens for Future Biomedical Research is to explore and identify biomarkers that inform the scientific understanding of diseases and/or their therapeutic treatments. The overarching goal is to use such information to develop safer, more effective drugs, and/or to ensure that subjects receive the correct dose of the correct drug at the correct time. |
|
E.3 | Principal inclusion criteria |
1. Be a healthy, Japanese male between the ages of 16 years and 0 days and 26 years and 364 days.
2. Fully understand (or, for minor subjects, parent/legal guardian and subject) study procedures, alternative treatments available, the risks involved with the study, and voluntarily agrees to participate by giving written informed consent. The subject may also provide consent for Future Biomedical Research. However, the subject may participate in the main trial without participating in Future Biomedical Research.
3. Agree to provide study personnel with a primary telephone number as well as an alternate telephone number for follow-up purposes
4. Have no clinical evidence of gross genital lesion suggesting sexually-transmitted disease and no clinically present external genital warts.
5. Show no temperature ≥37.5°C (oral) within 24 hours prior to vaccinations.
6. Agree to refrain from sexual activity (including vaginal and anal penetration and any genital contact) for 2 calendar days prior to any scheduled visit that includes sample collection, to avoid detection of viral DNA which has been deposited in the male genital area during sexual intercourse and is not the result of ongoing infection.
7. a) For HM: Subjects must be a heterosexual male, who has had exclusively female sexual partners, and has 1 to 5 lifetime female sexual partners at the time of enrollment.
b) For MSM: Subjects must identify themselves as a man who has sex with men, must have engaged in either insertive or receptive anal intercourse or oral sex with another male sexual partner within the past year, and have 0 to 5 lifetime male and/or female sexual partners at the enrollment.
|
|
E.4 | Principal exclusion criteria |
1. Is concurrently enrolled in clinical studies of investigational agents or studies involving collection of genital specimens.
2. Has history of known prior vaccination with an HPV vaccine or plans to receive the HPV vaccine outside of the study.
3. Has receipt of inactivated vaccines within 14 days prior to enrollment or receipt of live virus vaccines within 28 days prior to enrollment.
4. Has history of external genital warts, or has clinically present external genital warts at Day 1.
5. Has history of severe allergic reaction (e.g., swelling of the mouth and throat, difficulty breathing, hypotension or shock) that required medical intervention.
6. Is allergic to any vaccine component, including aluminum, yeast, or BENZONASE™ (nuclease, Nycomed [used to remove residual nucleic acids from this and other vaccines]).
7. Has received any immune globulin or blood derived products within the 6 months prior to the first injection, or plan to receive any through Month 7 of the study.
8. Has history of splenectomy or is currently immunocompromised or has been diagnosed as having a congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease, or other auto immune condition.
9. Is receiving, or has received in the year prior to enrollment the following immunosuppressive therapies: radiation therapy, cyclophosphamide, azathioprine, methotrexate, any chemotherapy, cyclosporin, leflunomide, TNF-α antagonists, monocolonal antibody therapies (including rituximab), intravenous gamma globulin, antilymphocyte sera, or other therapy known to interfere with the immune response. With regard to systemic corticosteroids, a subject will be excluded if he is currently receiving steroid therapy, has recently (defined as within 2 weeks of enrollment) received such therapy, or has received 2 or more courses of high dose corticosteroids (orally or parenterally) lasting at least 1 week in duration in the year prior to enrollment. Subjects using inhaled, nasal, or topical corticosteroids are considered eligible for the study.
10. Has known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
11. Has history of recent (within the last 12 months) or ongoing alcohol or drug abuse. Alcohol and drug abusers are defined as those who drink or use drugs despite recurrent social, interpersonal, and legal problems as results of alcohol or drug use.
12. Has a history or current evidence of any condition, therapy, lab abnormality or other circumstance that might confound the results of the study, or interfere with the subject’s participation for the full duration of the study, such that it is not in the best interest of the subject to participate.
13. Is unlikely to adhere to the study procedures, keep appointments, or is planning to relocate during the study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary Efficacy Endpoint: Incidence of HPV 6-, 11-, 16- or 18-related persistent infection. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
In the primary per-protocol analysis, follow-up for efficacy begins following the Month 7 visit and efficacy is assessed to end of the study (Month 36 visit). |
|
E.5.2 | Secondary end point(s) |
Efficacy Endpoints:
•Incidence of HPV 6-, 11-, 16- or 18-related persistent infection
•Incidence of HPV 6-, 11-, 16- or 18-related persistent infection, condyloma acuminata, PIN, penile, perianal or perineal cancer
•Seroconversion percentages to each of HPV 6, 11, 16, and 18
Safety Endpoints:
•Incidence of vaccine-related serious adverse experiences occurring any time during the study,
•Non-serious adverse experiences occurring Day 1 through Day 15 following any vaccination
•Serious adverse experiences occurring Day 1 through Day 15 following any vaccination
•New medical condition occurring any time during the study
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
In the per-protocol analysis, follow-up for efficacy begins following the Month 7 visit and efficacy is assessed to end of the study (Month 36 visit). Safety is assessed from Day 1 to Month 36. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LDA (Last Data Available)
The overall trial ends when the Sponsor receives the last assay results (e.g. serum, swab, and biopsy) or patient data from the last study-related phone-call or visit. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 7 |